Anirban Maitra, Director of Perlmutter Cancer Center at NYU Langone Health, shared on X:
”KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in Pancreatic Cancer.
Highlighting the role MYC plays in dampening intrinsic interferon signaling and KRASi response.
——
Title: KRASG12D-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer
Authors: Yehan Zhang, Shijie Tang, Yi Zhang, Jiahui Liu, Xiaohan Shi, Yikai Li, Yunguang Li, Huan Wang, Chaoliang Zhong, Maoyuan Sun, Wenjie Li, Yiqin Zhu, Weiwei Yang, Yun Zhao, Shiwei Guo, Zhongjun Wu, Lin Wang, Gang Jin, Dong Gao
——
Title: Intrinsic resistance to KRAS inhibition: Interfering with interferon
Authors: Borja Miguel-López, Matthias Drosten
Reminded of Lowe Lab, Nature paper wherein interferon-encompassing chromosome 9p21.3 deletions act as mediators of immune evasion and metastasis.
How pancreatic cancers respond to KRASi and if PRMT5i can augment (when MTAP co-deleted) is a question.”
Title: MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis
Authors: Francisco M. Barriga, Kaloyan M. Tsanov, Yu-Jui Ho, Noor Sohail, Amy Zhang, Timour Baslan, Alexandra N. Wuest, Isabella Del Priore, Brigita Meškauskaitė, Geulah Livshits, Direna Alonso-Curbelo, Janelle Simon, Almudena Chaves-Perez, Dafna Bar-Sagi, Christine A. Iacobuzio-Donahue, Faiyaz Notta, Ronan Chaligne, Roshan Sharma, Dana Pe’er, Scott W. Lowe
You can also read:
